Esophagectomy Outcomes in the Endoscopic Mucosal Resection Era

Slides:

Advertisements

Similar presentations

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E

Advertisements

Robert M. Kaplan, PhD, Qiankun Sun, PhD, Keith S

Usman Ahmad, MD, Zuoheng Wang, PhD, Ayesha S

Elizabeth A. David, MD, David T

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Extended Pleurectomy-Decortication–Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years Joseph.

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes Meng S. Shao, MD, Andrew T. Wong, MD,

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Benny Weksler, MD, Jennifer L. Sullivan, MD

Masatsugu Hamaji, MD, Stephen D. Cassivi, MD, K

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Andrew C. Chang, MD, Andrzej S. Kosinski, PhD, Daniel P

Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non- Small Cell Lung Cancer Matthew P. Smeltzer, PhD, Nicholas Faris, MDiv,

Extended Pleurectomy-Decortication–Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years Joseph.

Trevor Williams, MD, MPH, Brian C

Christopher W. Seder, MD, Mark S. Allen, MD, Francis C

Log Odds of Positive Lymph Nodes Predicts Survival in Patients After Resection for Esophageal Cancer Jinlin Cao, MD, Ping Yuan, MD, Honghai Ma, MD, Peng.

Salvage Resections for Recurrent or Persistent Cancer of the Proximal Esophagus After Chemoradiotherapy Colin Schieman, MD, Dennis A. Wigle, MD, PhD,

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Super-Charged Pedicled Jejunal Interposition Performance Compares Favorably With a Gastric Conduit After Esophagectomy Elizabeth H. Stephens, MD, PhD,

Prognostic Value of Different Lymph Node Staging Methods in Esophageal Squamous Cell Carcinoma After Esophagectomy San-Gang Wu, MD, Feng-Yan Li, MD,

Gal Levy, MD, Mark A. Cordes, MD, Alexander S. Farivar, MD, Ralph W

Esophageal Resection for Cancer of the Esophagus: Long-Term Function and Quality of Life Allison J McLarty, MD, Claude Deschamps, MD, Victor F Trastek,

The Use of Self-Expanding Silicone Stents in Esophagectomy Strictures: Less Cost and More Efficiency Robert C.G. Martin, MD, Charles Woodall, MD, Ryan.

Castigliano M. Bhamidipati, DO, MS, George J

The Model for End-Stage Liver Disease (MELD) Predicts Early and Late Outcomes of Cardiovascular Operations in Patients With Liver Cirrhosis Naoto Morimoto,

Clinical T2-T3N0M0 Esophageal Cancer: The Risk of Node Positive Disease Brendon M. Stiles, MD, Farooq Mirza, MD, Anthony Coppolino, MD, Jeffrey L. Port,

Jong Ho Cho, MD, Masatsugu Hamaji, MD, Mark S. Allen, MD, Stephen D

Loretta Erhunmwunsee, MD, Brian C

Complex Esophageal Reconstruction Procedures Have Acceptable Outcomes Compared With Routine Esophagectomy Jessica M. Moore, BS, Craig M. Hooker, PhD,

K. Robert Shen, MD, Mark S. Allen, MD, Stephen D

A Randomized Controlled Trial of Bupivacaine Through Intracostal Catheters for Pain Management After Thoracotomy Mark S. Allen, MD, Lisa Halgren, RN,

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer Masatsugu Hamaji, MD, Mark S. Allen,

Brendon M. Stiles, MD, Farooq Mirza, MD, Jeffrey L. Port, MD, Paul C

Michelle C. Ellis, MD, Brian S. Diggs, PhD, John T. Vetto, MD, Paul H

Mark D. Iannettoni, MD, William R. Lynch, MD, Kalpaj R

Philip W. Smith, MD, Hongkun Wang, PhD, Leo M. Gazoni, MD, K

Elizabeth H. Stephens, MD, PhD, Arlene M. Correa, PhD, Min P

Eduardo Crema, PhD, MD, Lara B. P. Ribeiro, Juverson A. Terra, Alex A

Trevor Williams, MD, MPH, Brian C

Theolyn N. Price, MD, Mark S. Allen, MD, Francis C

Surgical Resection of Rare Esophageal Cancers

Treatment of Postsurgical Chylothorax

Utility of Routine PET Imaging to Predict Response and Survival After Induction Therapy for Non-Small Cell Lung Cancer Stephen A. Barnett, MBBS, Robert.

Use of Amiodarone After Major Lung Resection

Karen M. Harrison–Phipps, MD, Francis C. Nichols, MD, Cathy D

Elliot Wakeam, MD, MPH, James P. Byrne, MD, Gail E

John Agzarian, MD, MPH, Sue L. Visscher, PhD, Ariel W

Number of Lymph Nodes Associated With Maximal Reduction of Long-Term Mortality Risk in Pathologic Node-Negative Non–Small Cell Lung Cancer Raymond U.

The Prognostic Value of the Number of Negative Lymph Nodes in Esophageal Cancer Patients After Transthoracic Resection Po-Kuei Hsu, MD, Chien-Sheng Huang,

Robert R. McMillan, MD, MPH, Camelia S. Sima, MD, MS, Nicole H

Survival After Surgical Resection of Stage IV Esophageal Cancer

Variation in Hospital Adoption Rates of Video-Assisted Thoracoscopic Lobectomy for Lung Cancer and the Effect on Outcomes Zaid M. Abdelsattar, MD, MS,

Felix G. Fernandez, MD, Onkar Khullar, MD, Seth D

Predictors of Long-Term Survival After Resection of Esophageal Carcinoma With Nonregional Nodal Metastases Paul C. Lee, MD, Jeffrey L. Port, MD, Subroto.

Outcomes After Transhiatal and Transthoracic Esophagectomy for Cancer

Extent of Lymphadenectomy Is Associated With Improved Overall Survival After Esophagectomy With or Without Induction Therapy Pamela Samson, MD, MPHS,

Phillip G. Rowse, MD, Dawn E

Surgical Treatment for Limited-Stage Primary Small Cell Cancer of the Esophagus Dongrong Situ, MD, Yongbin Lin, MD, PhD, Hao Long, MD, PhD, Lanjun Zhang,

Robert M. Kaplan, PhD, Qiankun Sun, PhD, Keith S

Anirudh Vinnakota, MS, Robert Stewart, MD, Gosta Pettersson, MD, PhD

Zaid M. Abdelsattar, MD, MS, K

Predictors of Recurrent Pulmonary Metastases and Survival After Pulmonary Metastasectomy for Colorectal Cancer Shanda H. Blackmon, MD, MPH, Elizabeth.

Specialty Training and Mortality After Esophageal Cancer Resection

Adhering to Quality Measures in Esophagectomy Is Associated With Improved Survival in All Stages of Esophageal Cancer Pamela Samson, MD, MPHS, Varun.

Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer? Anna Lee, MD, MPH, Andrew T.

Bullectomy for Symptomatic or Complicated Giant Lung Bullae

Neoadjuvant Chemoradiation Therapy Is Beneficial for Clinical Stage T2 N0 Esophageal Cancer Patients Due to Inaccurate Preoperative Staging Jennifer.

Mark I. Block, MD The Annals of Thoracic Surgery

Jenifer L. Marks, MD, Wayne Hofstetter, MD, Arlene M

Presentation transcript:

Esophagectomy Outcomes in the Endoscopic Mucosal Resection Era Karen J. Dickinson, MBBS FRCS (Engl), Kenneth Wang, MD, Lizhi Zhang, MD, Mark S. Allen, MD, Stephen D. Cassivi, MD, MS, Francis C. Nichols, MD, Robert Shen, MD, Dennis A. Wigle, MD, PhD, Shanda H. Blackmon, MD, MPH The Annals of Thoracic Surgery Volume 103, Issue 3, Pages 890-897 (March 2017) DOI: 10.1016/j.athoracsur.2016.08.062 Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 Overall survival in the cohort of patients with cT1 esophageal adenocarcinoma undergoing endoscopic mucosal resection and then esophagectomy. The Annals of Thoracic Surgery 2017 103, 890-897DOI: (10.1016/j.athoracsur.2016.08.062) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 Patients with a moderate risk (blue line) of lymph node metastases (LN mets) on preoperative scoring have poorer 5-year survival (54%) than high-risk (red line) patients (84% survival; p = 0.04). The Annals of Thoracic Surgery 2017 103, 890-897DOI: (10.1016/j.athoracsur.2016.08.062) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 3 Patients with lymph nodes involved (red line) at the time of esophagectomy had decreased 5-year survival of 51% compared with 84% in lymph node-negative patients (blue line; p = 0.04). The Annals of Thoracic Surgery 2017 103, 890-897DOI: (10.1016/j.athoracsur.2016.08.062) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions